Bacillus calmette-guerin live antigen, unspecified substrain for tuberculosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Jul 2023: Trial registered, NCT05947890
  2. 30 Jan 2024: Trial started, NCT05947890

The trials

NCT05947890: Evaluating the Safety and Immunogenicity of MTBVAC

State
Under way
Phase
Phase 2
People
276 planned
Started
30 Jan 2024
Primary completion
Nov 2027
Arms
1.1b - Adolescents and adults without HIV and negative interferon-gamma release assay, 1.2b - Adolescents and adults without HIV and positive interferon-gamma release assay, 2.1.b - Adolescents and adults with well-controlled HIV and negative interferon-gamma release assay, 2.2 b- Adolescents and adults with well-controlled HIV and positive interferon-gamma release assay, 3.1 b- Adults with well-controlled HIV and negative interferon-gamma release assay, 3.2 b- Adults with well-controlled HIV and positive interferon-gamma release assay
Results
None posted
  1. 17 Jul 2023: Trial registered
  2. 30 Jan 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Bcg, BCG Solution, Bacillus Calmette Guerin Vaccine.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.